The EU Commission imposes fines totalling € 145 M on Danish pharmaceutical group over “pay-for-delay” agreements (Lundbeck)

On 19 June 2013, the European Commission announced that it had imposed a fine of € 93.8 million on Danish pharmaceutical group Lundbeck and fines totalling € 52.2 million on several generic medicines producers over their conclusion of so-called “pay-for-delay” agreements intended to hinder the market entry of generic versions of Lundbeck's blockbuster antidepressant Citalopram in the EEA. This is the first time the Commission dealt specifically with these pay-for-delay agreements under the EU competition rules. Following several dawn raids in 2008, 2009 and 2010, the Commission opened a formal investigation into Lundbeck's practices on 7 January 2010 and issued a formal Statement of Objections (“SO”) against Lundbeck and certain generics producers in July 2012. When it opened its

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Johan Van Acker, Dina Ansari, The EU Commission imposes fines totalling € 145 M on Danish pharmaceutical group over “pay-for-delay” agreements (Lundbeck), 19 June 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 53996

Visites 880

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues